|
News FDA approves Inlyta to treat patients with a type of advanced kidney cancer
The U.S. Food and Drug Administration approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer. |
|
Leaflet Drug Naptumomab estafenatox
Naptumomab estafenatox for the treatment of renal cell carcinoma |
|
News Pfizer Files For European Regulatory Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma
Pfizer Inc. announced that the European Medicines Agency (EMA) has accepted Pfizer’s filing for regulatory review of axitinib for patients with advanced renal cell carcinoma (RCC) after failure of prior systemic treatment. |
|
Leaflet Drug 4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline
Renal cell carcinoma (also called cancer of the kidney or renal adenocarcinoma) is a disease in which cancer (malignant) cells are found in certain tissues of the kidney. |